Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 6

1.

Modulation of the anti-cancer efficacy of microtubule-targeting agents by cellular growth conditions.

Dorsey JF, Dowling ML, Kim M, Voong R, Solin LJ, Kao GD.

Cancer Biol Ther. 2010 May 15;9(10):809-18.

2.

Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and paclitaxel have cooperative in vivo effects against glioblastoma multiforme cells.

Dorsey JF, Mintz A, Tian X, Dowling ML, Plastaras JP, Dicker DT, Kao GD, El-Deiry WS.

Mol Cancer Ther. 2009 Dec;8(12):3285-95. doi: 10.1158/1535-7163.MCT-09-0415.

3.

The HDAC inhibitor panobinostat (LBH589) inhibits mesothelioma and lung cancer cells in vitro and in vivo with particular efficacy for small cell lung cancer.

Crisanti MC, Wallace AF, Kapoor V, Vandermeers F, Dowling ML, Pereira LP, Coleman K, Campling BG, Fridlender ZG, Kao GD, Albelda SM.

Mol Cancer Ther. 2009 Aug;8(8):2221-31. doi: 10.1158/1535-7163.MCT-09-0138. Epub 2009 Aug 11.

4.

TRAIL inactivates the mitotic checkpoint and potentiates death induced by microtubule-targeting agents in human cancer cells.

Kim M, Liao J, Dowling ML, Voong KR, Parker SE, Wang S, El-Deiry WS, Kao GD.

Cancer Res. 2008 May 1;68(9):3440-9. doi: 10.1158/0008-5472.CAN-08-0014.

5.

Caspase-mediated specific cleavage of BubR1 is a determinant of mitotic progression.

Kim M, Murphy K, Liu F, Parker SE, Dowling ML, Baff W, Kao GD.

Mol Cell Biol. 2005 Nov;25(21):9232-48. Erratum in: Mol Cell Biol. 2007 Mar;27(5):1991.

6.

Inactivation of the mitotic checkpoint as a determinant of the efficacy of microtubule-targeted drugs in killing human cancer cells.

Lee EA, Keutmann MK, Dowling ML, Harris E, Chan G, Kao GD.

Mol Cancer Ther. 2004 Jun;3(6):661-9.

Supplemental Content

Loading ...
Support Center